AI-driven • Genomic research
Galatea Bio is a biotechnology company that uses AI-driven genomic research and clinical genetic testing to advance precision medicine and improve genetic risk analysis, biomarker discovery, and clinical trials optimization.
Non-opioid • Pain treatments
Latigo Biotherapeutics develops non-opioid pain treatments, focusing on selective Nav1.8 inhibitors.
Biotechnology • Drug Discovery
Eikon Therapeutics develops new medicines using advanced technologies like single-molecule tracking and high-performance computing to accelerate drug discovery and development.
Biotechnology • In vivo cell therapies
Umoja Biopharma is a biotechnology company focused on developing in vivo CAR T cell therapies for oncology and autoimmune diseases using its VivoVec™ gene delivery technology.
Epigenetic editing • Genetic medicines
nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.
Biotechnology • Autoimmune Diseases
Nuvig Therapeutics is a biotechnology company developing treatments for autoimmune diseases that do not rely on immunosuppression.
Biotechnology • Immuno-corrective therapies
Autoimmunity BioSolutions develops next-generation immuno-corrective therapies targeting genetically-defined subpopulations of patients with autoimmune diseases.
Biotechnology • Immunotherapeutics
Valora Therapeutics Inc. is a biotechnology company developing novel immunotherapeutics using its proprietary AbLec platform to modulate glyco-immune checkpoints.
Biotechnology • Central Nervous System
Leal Therapeutics is a biotechnology company developing treatments for central nervous system disorders, focusing on amyotrophic lateral sclerosis (ALS) and schizophrenia.
AI-driven • Computational protein design
Archon Biosciences develops AI-driven Antibody Cages to enhance antibody treatments by improving target engagement and biodistribution.
Biotechnology • Neuromedicines
Axonis Therapeutics is a biotechnology company developing novel neuromedicines targeting neurological disorders like epilepsy and pain.
Therapeutic development • Protein targeting
Passkey Therapeutics develops novel therapies that target rare protein combinations to treat complex diseases like cancer and autoimmune disorders.
Biotechnology • Small Molecule Drug Discovery
Terray Therapeutics integrates ultra-high throughput experimentation with generative AI, biology, medicinal chemistry, automation, and nanotechnology to transform small molecule drug discovery.
Biotechnology • Small molecule therapeutics
858 Therapeutics is a biotechnology company developing small molecule therapeutics for oncology and immunology, with a lead asset, ETX-19477, in Phase 1 trials for advanced solid tumors.
Multabody™ platform • Oncology
Radiant Biotherapeutics develops innovative therapies using its proprietary Multabody™ platform to target oncology, inflammation, immunology, and infectious diseases.
Antibody Therapeutics • Preclinical Development
Ability Biologics is a biotech startup focused on creating next-generation antibody therapeutics for unmet medical needs using their proprietary AI platform, AbiLeap™.
Biotechnology • Immunomodulators
Odyssey Therapeutics is a biotech firm specializing in developing precision immunomodulators and oncology medicines, with plans to advance multiple therapeutic programs into clinical studies.
Biotechnology • Drug Discovery
Seismic Therapeutic is a biotechnology firm specializing in the development of immunology drugs using a machine learning-enabled platform to advance its biologics pipeline through clinical trials.
Precision Psychiatry • Brain Biomarkers
Alto Neuroscience specializes in precision psychiatry, developing targeted medicines based on its Precision Psychiatry Platform™, which utilizes brain biomarkers to match patients with appropriate treatments.
Biotech • Antibody treatments
Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.
Biotech • Immunotherapy
Deka Biosciences is a biotech company that aims to improve immunotherapy treatments by combining biology with precision medicine, specifically through their investigational new drug, DK210 (EGFR), which has dissociated IL-2 potency from toxicity.
Biotechnology • Neuropsychiatric Disorders
Arialys Therapeutics is a biotechnology company that develops precision medicines to target pathogenic autoantibodies in the central nervous system, with a focus on treating neuropsychiatric diseases caused by autoimmunity.
Biotechnology • Autoimmune Diseases
ROME Therapeutics is a biotechnology company that develops breakthrough medicines for serious diseases, with a focus on an inhibitor of LINE-1 reverse transcriptase for autoimmune diseases, using their proprietary data science platform to identify active repeat elements and assess their roles in disease.